A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT06029127 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Gimistotug
DRUG: Docetaxel
DRUG: BGB-15025

Sponsor

BeiGene